Emerging biotechnologies: full report - Nuffield Council on Bioethics

More documents

Recommendations

Info

E m e r g i n g b i o t e c h n o l o g i e s commercialisation problems 9.36, 9.38– 9.39, 9.41 incentivising 9.60–9.69 type 2 emerging <strong>biotechnologies</strong> 9.34, 9.37 commercialisation problems 9.40 incentivising 9.70 type 3 emerging <strong>biotechnologies</strong> 9.34, 9.37 Type I and Type II errors 5.31 UK Genetic Testing Network 8.25 uncertainty 3.1, 3.3–3.12, 3.37–3.38, 10.4 commercialisation problems 9.48–9.51 effects of framing 3.32–3.34 managing 3.26–3.36 public discourse ethics 4.44 public perspectives 5.3 regulatory aspects 8.12–8.14, 8.35 risk and 3.10–3.12 varieties of 3.5–3.9 uncontrolled uses 3.9, Box 3.1 Understanding risk (1996, US National Research <strong>Council</strong>) 5.24 unintended consequences 1.1, 3.8 United Kingdom (UK) GM food crops 2.8, 5.22, 8.13, 8.18, 8.29 'good at research, bad at commercialisation' 7.21, 7.23–7.32 health impact fund 9.62–9.63 importance of research impact 6.38–6.42 regulatory systems 8.21–8.25 research and innovation policy 7 research funding 6.7–6.10 research settings 6.5 see also Government, UK United States (US) GM crops 2.8, 8.18 importance of research impact 6.38 influences over the media 5.15–5.16 orphan drugs 9.20 patent protection 9.23–9.24 research funding 6.10 universities 6.5 impact agenda 6.38–6.46 research and profit-seeking 9.10–9.12 unknown unknowns 3.11 upstream public engagement 5.40–5.42 utilitarian ethics 4.24–4.25 utility, research 6.42–6.43 industry 6.27–6.35 procedural narratives 2.36–2.38 see also expectations water power Box 3.3 Wellcome Trust 6.14, 7.18, 7.46, 7.58 Wellcome Trust Sanger Institute 6.5 winners, technological 1.26 wisdom of repugnance 4.12 World Health Organization (WHO) 8.25, 9.61 World Wide Web 3.8, 5.11 xenobiology 2.22 xeno-nucleic acid 2.22 xenotransplantation 2.11, 2.42 yuck factor 4.12 vaccination 4.35, Box 1.1 vaccines, production of 8.23 'valley of death' 7.24, 9.42–9.43 J. Craig Venter Institute 3.18, Box 3.2 venture capitalism 6.13, 6.22, 7.40, 9.7, 9.43 viral genomes, synthetic 2.20 virtual patients 1.14, 6.12 virtues, procedural 4.43–4.55, 4.57 visions, biotechnology 1.4, 2.29–2.38, 2.45 ambiguous 3.14–3.16 future 2.34–2.35 208
Previous <strong>Nuffield</strong> <strong>Council</strong> Reports Novel techniques for the prevention of mitochondrial DNA disorders: an ethical review Published June 2012 Human bodies: donation for medicine and research Published October 2011 Biofuels: ethical issues Published April 2011 Medical profiling and online medicine: the ethics of ‘personalised healthcare’ in a consumer age Published October 2010 Dementia: ethical issues Published October 2009 Public health: ethical issues Published November 2007 The forensic use of bioinformation: ethical issues Published September 2007 Critical care decisions in fetal and neonatal medicine: ethical issues Published November 2006 Genetic Screening: a Supplement to the 1993 Report by the <strong>Nuffield</strong> <strong>Council</strong> on Bioethics Published July 2006 The ethics of research involving animals Published May 2005 The ethics of research related to healthcare in developing countries: a follow-up Discussion Paper Published March 2005 The use of genetically modified crops in developing countries: a follow-up Discussion Paper Published December 2003 Pharmacogenetics: ethical issues Published September 2003 Genetics and human behaviour: the ethical context Published October 2002 The ethics of patenting DNA: a discussion paper Published July 2002 The ethics of research related to healthcare in developing countries Published April 2002 Stem cell therapy: the ethical issues – a discussion paper Published April 2000 The ethics of clinical research in developing countries: a discussion paper Published October 1999 Genetically modified crops: the ethical and social issues Published May 1999 Mental disorders and genetics: the ethical context Published September 1998 Animal-to-human transplants: the ethics of xenotransplantation Published March 1996 Human tissue: ethical and legal issues Published April 1995 Genetic screening: ethical issues Published December 1993 Published by <strong>Nuffield</strong> <strong>Council</strong> on Bioethics 28 Bedford Square London WC1B 3JS Printed in the UK © <strong>Nuffield</strong> <strong>Council</strong> on Bioethics 2012 ISBN 978-1-904384-27-4
Page 1 and 2:
Emerging b
Page 3:
Emerging b
Page 6 and 7:
Secretariat Hugh Whittall (Director
Page 9:
Foreword 1 The use of living organi
Page 13:
Terms of reference 1. To examine co
Page 16 and 17:
Applying public ethics: towards a p
Page 19 and 20:
E m e r g i n g b i o t e c h n o l
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29:
Page 32 and 33:
Page 35:
Part 1 Understanding emerging <stro
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 51 and 52:
Chapter 2 Biotechnology promises an
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Chapter 3 The threefold challenge o
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 105 and 106:
Chapter 5 Public perspectives
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Chapter 6 Research
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 181 and 182:
Chapter 9 Commercialisation
Page 183 and 184:
Page 185 and 186:
Page 187 and 188: E m e r g i n g b i o t e c h n o l
Page 203 and 204: Chapter 10 Conclusions: emerging <s
Page 209 and 210: Appendices
Page 237: E m e r g i n g b i o t e c h n o l
show all

Emerging biotechnologies: full report - Nuffield Council on Bioethics

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?